Chapter 52: Early-Onset Psychotic Disorders

Early-onset psychotic disorders represent a severe subset of psychotic conditions that emerge during childhood or adolescence, with very early-onset schizophrenia occurring before age 13 and standard early-onset presentations occurring before age 18. Psychotic symptoms manifest across two primary dimensions: positive symptoms including hallucinations, delusions, disorganized speech and thought patterns, and catatonic features; and negative symptoms characterized by blunted affect, motivational deficits, alogia, and social withdrawal. While transient psychotic-like experiences occur relatively frequently in developing children, persistent psychotic disorders remain uncommon, affecting less than 0.04% of the pediatric population. The etiology of early-onset psychotic disorders involves multiple interacting factors, particularly substantial genetic loading and specific genetic vulnerabilities such as 22q11.2 microdeletions, combined with neurodevelopmental disruptions including abnormal synaptic pruning processes and progressive cortical gray matter reduction. Environmental contributors including trauma exposure, perinatal complications, and adolescent cannabis initiation further increase disorder risk. Diagnostic complexity in younger patients arises from developmental differences in symptom expression—children frequently describe perceptual disturbances in imaginative or multimodal formats and may present with loosely structured false beliefs rather than systematized delusions—requiring careful differentiation from autism spectrum presentations, trauma-related disorders, early-onset bipolar disorder with psychotic features, and substance-related psychosis. The longitudinal course typically involves persistent impairment across academic, social, and occupational functioning, progressive cognitive decline, and substantial suicide risk particularly within the initial decade following initial diagnosis. Comprehensive treatment requires integrated approaches combining antipsychotic pharmacotherapy with medications such as risperidone, olanzapine, and aripiprazole, and clozapine for treatment-resistant presentations, alongside psychosocial interventions including family-based psychoeducation, cognitive remediation programs, coordinated school-based support, and specialized first-episode psychosis treatment protocols. Early identification and intervention optimize functional outcomes, though significant long-term disability remains prevalent, necessitating sustained multimodal clinical management across development.